🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Rituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness

RecruitingPhase 2Ages 18 Years - 70 YearsAllInstitute of Hematology & Blood Diseases Hospital…
NCT06254560 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Due to long-term dependence on platelet transfusion, some severe aplastic anemia (SAA) patients suffer platelet transfusion refractoriness (PTR). Unlike immune thrombocytopenia (ITP), glucocorticoids and human immunoglobulin (IVIg) are generally ineffective for PTR. Due to the lack of effective intervention methods, patients with PTR suffer increased platelet transfusions, bleeding events and treatment costs, prolonged hospital stays, and decreased survival rate. SAA with PTR has become a challenge for physicians. The experiment aims to explore the efficacy of rituximab in the treatment of SAA with PTR, and establish a new effective, safe treatment method with relatively low treatment cost.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Initial diagnosed SAA with PTR * Age\>18 years old, regardless of gender * Initial diagnosed SAA with PTR * Age\>18 years old, regardless of gender Exclusion Criteria: * Allergy to rituximab * Severe active infection * Hypogammaglobulinemia * Pregnant and lactating women * Heart failure (NYHA classification IV) * Individuals with epilepsy, dementia, and other mental disorders that require medication treatment who cannot understand or follow the research protocol * Chronic infections or other chronic diseases that may be risk to the experiment * The researchers believe that it is not suitable for participants
💊

What it tests

  • Rituximab
📍

Where

1 site
Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences
Tianjin, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy